Marian Sobhy Waheeb Azer | Pharmaceutical Sciences | Innovative Research Award

Published on by Top Pharmaceutical

Innovative Research Award

Marian Sobhy Waheeb Azer — Misr University for Science & Technology, Egypt

Marian Sobhy Waheeb Azer
Affiliation Misr University for Science & Technology
Country Egypt
Subject Area Pharmaceutical Sciences
Event International Top Pharmaceutical Awards
ORCID 0000-0003-1072-9893

Marian Sobhy Waheeb Azer is a researcher associated with pharmaceutical sciences whose ORCID record lists work on drug delivery, formulation development, and pharmacokinetic evaluation. The documented topics include a lamotrigine self-nanoemulsifying delivery system and a ciclopirox olamine emulgel formulation. These subjects reflect practical research interests in dosage-form design, pharmaceutical characterization, and the investigation of drug delivery performance. This article summarizes the available profile information and its relevance to the Innovative Research Award without assuming unverified bibliometric indicators or award outcomes.[1][2]

Abstract

This profile reviews the pharmaceutical research themes documented in Marian Sobhy Waheeb Azer’s ORCID record. The listed publications concern formulation development and drug delivery, including a solid self-nanoemulsifying system for lamotrigine and a topical emulgel containing ciclopirox olamine. These topics are relevant to pharmaceutical formulation, characterization, and evaluation of drug delivery systems. The available record supports a focused account of these research activities, but does not independently establish citation totals, an h-index, or an official award decision.[1][2]

Keywords

Pharmaceutical sciences; drug delivery systems; lamotrigine; self-nanoemulsifying drug delivery; pharmacokinetics; ciclopirox olamine; emulgel formulation; pharmaceutical characterization; formulation research; innovative research.

Introduction

Pharmaceutical research connects the design of dosage forms with the assessment of their properties and potential performance. Delivery-system development can investigate how formulation components influence drug solubilization, release, and absorption, while topical formulations address the requirements of local administration. Azer’s documented work sits within these broad areas. The available publication metadata provides a basis for describing the research topics, although detailed experimental results should be taken from the original articles rather than inferred from titles alone.[1][2]

Research Profile

The supplied ORCID profile identifies Marian Sobhy Azer and lists two research works. One is a 2020 journal article in Drug Design, Development and Therapy on the development, characterization, and in-vivo pharmacokinetic study of a lamotrigine solid self-nanoemulsifying drug delivery system. The other concerns the development and characterization of ciclopirox olamine emulgel for topical drug delivery, listed as published in 2014. The profile does not provide verified Scopus author metrics in the supplied document.[1][2]

Research Contributions

The lamotrigine study addresses a formulation approach designed to support drug delivery and includes characterization and in-vivo pharmacokinetic evaluation in its stated scope. Such work connects pharmaceutical development with the measurement of drug disposition, although specific outcomes require consultation of the full publication. The topical emulgel work focuses on a formulation containing ciclopirox olamine, illustrating a separate dosage-form application. Together, the listed topics show engagement with both systemic delivery research and topical formulation development.[1][2]

Publications

The ORCID profile lists two publications related to pharmaceutical sciences. One focuses on the development and evaluation of a lamotrigine drug delivery system, while the other examines the formulation and characterization of ciclopirox olamine emulgel for topical drug delivery.[1][2]

Research Impact

The documented subjects are relevant to formulation scientists and pharmaceutical researchers investigating delivery strategies and dosage-form characteristics. However, research impact should be assessed using verified evidence such as citation records, independent adoption, reproducibility, and influence on subsequent work. Citation counts and h-index values are not present in the supplied ORCID document, so no numerical impact claim is made here. Further evaluation can use indexed publication records and the full-text articles.[1][3]

Award Suitability

The listed work provides subject-matter relevance to an Innovative Research Award in pharmaceutical sciences, particularly through formulation development and drug delivery investigations. A fair assessment would examine originality, methodological quality, reproducibility, publication integrity, practical significance, and the candidate’s specific contribution to each study. The information presented here is a profile summary, not confirmation of nomination, selection, or receipt of an award. Final eligibility and recognition must be verified with the award organizer.[4]

Conclusion

Marian Sobhy Waheeb Azer’s supplied ORCID record documents research related to lamotrigine delivery systems and ciclopirox olamine topical formulation. These subjects are pertinent to pharmaceutical formulation and evaluation. The record offers a starting point for academic recognition, while a complete assessment requires the original articles, verified bibliometric data, and evidence of individual research contributions. Readers should consult the linked primary sources for publication details and the official award website for current event information.

References

  1. Azer, M. S. (2020). Development, Characterization, and in-vivo Pharmacokinetic Study of Lamotrigine Solid Self-Nanoemulsifying Drug Delivery System. Drug Design, Development and Therapy. DOI: 10.2147/DDDT.S263898.
  2. Azer, M. S. (2014). Development and Characterization of Ciclopirox Olamine Emulgel for Topical Drug Delivery. Inventi Impact: Pharm Tech. Publication details transcribed from the supplied ORCID profile. https://inventi.in/journal/article/1/7319/Inventi%20Impact:%20Pharm%20Tech/Pharmaceutical
  3. ORCID. (n.d.). Marian Sobhy Azer: Researcher record and works. https://orcid.org/0000-0003-1072-9893.
  4. International Top Pharmaceutical Awards. (n.d.). Official award website. Award eligibility and recognition details should be confirmed with the organizer. https://toppharmaceutical.org/.

Pallab Mandal | Pharmacology | Best Innovation Award

Published on by Top Pharmaceutical

Best Innovation Award

Pallab Mandal – Ami Polymer Pvt Ltd

Pallab Mandal
Affiliation Ami Polymer Pvt Ltd
Country India
Scopus ID 57190006013
Documents 17
Citations 88
h-index 6
Subject Area Pharmacology
Event International Top Pharmaceutical Awards
ORCID 0000-0003-3869-7678

Pallab Mandal is a pharmaceutical research scientist associated with bioanalytical research, drug analysis, and pharmacokinetic investigations. This academic recognition profile summarizes his documented research activities and publication record in pharmacology and pharmaceutical analysis. According to his ORCID record, Mandal’s research interests include liquid chromatography tandem mass spectrometry, pharmacokinetics, pharmacodynamics, bioequivalence studies, drug analysis in human plasma, metabolite analysis, and protein analysis. His listed professional activities also include bioanalytical research, university teaching, and pharmaceutical association membership. [1]

Abstract

Pallab Mandal’s documented publications address pharmaceutical analysis, analytical method development, bioanalytical validation, and pharmacokinetic investigations. His work includes the application of liquid chromatography tandem mass spectrometry to pharmaceutical compounds and biological samples. These research themes provide the academic context for considering his profile for the Best Innovation Award. The article summarizes available records without asserting an independently confirmed award decision. [1]

Keywords

Pallab Mandal, Best Innovation Award, pharmacology, bioanalysis, LC-MS/MS, bioequivalence, pharmaceutical analysis, pharmacokinetics, analytical method validation, drug development.

Introduction

Pharmaceutical research depends on reliable analytical procedures to identify and quantify drug compounds. Validated bioanalytical methods support the measurement of substances in biological samples and can contribute to pharmacokinetic and bioequivalence investigations. Mandal’s publication record addresses these areas through analytical methods developed for a range of pharmaceutical compounds. [2]

Research Profile

The supplied ORCID record identifies Mandal as an LC-MS/MS bioanalyst and research scientist involved in bioequivalence studies. It records professional bioanalytical employment beginning in 2015, university-related teaching activity, and postgraduate research affiliation. His professional record also lists membership in the Indian Pharmaceutical Association. [1]

Research Contributions

Mandal’s listed studies investigate analytical approaches for compounds including miltefosine, azelnidipine, vilazodone, diosmetin, hesperetin, metformin, and teneligliptin. Several publications describe LC-MS/MS methods for human plasma analysis and pharmacokinetic applications. His research record also includes work on pharmaceutical packaging and drug-analysis procedures, reflecting interests in analytical reliability and pharmaceutical practice. [2] [3]

Publications

Representative publications listed in his ORCID record include a pharmaceutical packaging audit published in 2022, a miltefosine analytical method study from 2022, an azelnidipine bioanalytical method study from 2022, a vilazodone quantification study from 2021, and a diosmetin and hesperetin analysis from 2019. The DOI links in the references provide direct access to these bibliographic records and their available publication details. [4] [5]

Research Impact

The supplied profile metrics report 17 documents, 88 citations, and an h-index of 6. These figures are provided for this article and have not been independently verified against a live database. Citation counts may change over time or differ between platforms. The publication topics indicate potential practical relevance to pharmaceutical analysis, although individual findings should be assessed through their methods, results, and reproducibility. [1]

Award Suitability

Mandal’s research themes provide a basis for consideration in a pharmaceutical innovation recognition category. A comprehensive assessment should examine methodological originality, reproducibility, practical application, documented individual contributions, and independent peer review. The listed publications establish relevant research activity, but award eligibility and final selection remain matters for the award organizers and their evaluation process.

Conclusion

Pallab Mandal’s research profile focuses on pharmaceutical bioanalysis, LC-MS/MS-based analytical methods, and pharmacokinetic applications. His listed publications cover multiple drug compounds and related pharmaceutical topics. This Best Innovation Award article presents a structured academic overview with linked researcher records and DOI references for readers seeking to examine the available evidence independently.

References

  1. ORCID. (n.d.). Pallab Mandal: Researcher record and works. ORCID. https://orcid.org/0000-0003-3869-7678
  2. Mandal, P., et al. (2022). An audit on design of pharmaceutical packaging. Journal of Packaging Technology and Research. https://doi.org/10.1007/s41783-022-00141-8
  3. Mandal, P., et al. (2022). Analytical method development and validation of miltefosine by liquid chromatography tandem mass spectrometry. Research Journal of Pharmacy and Technology. https://doi.org/10.52711/0974-360x.2022.00693
  4. Mandal, P., et al. (2022). A novel validated bioanalytical method for azelnidipine in Indian human plasma by LC-MS/MS. Indian Drugs. https://doi.org/10.53879/id.59.05.12787
  5. Mandal, P., et al. (2021). Determination and quantitation of vilazodone hydrochloride in human plasma by LC-ESI-MS/MS. Journal of Analytical & Pharmaceutical Research. https://doi.org/10.15406/japlr.2021.10.00361

Shweta Patel | Women Researcher Award | Pharmaceutical

Published on by Top Pharmaceutical

Women Researcher Award

Shweta Patel — Gokul Global University, India

Shweta Patel
Affiliation Gokul Global University
Country India
Scopus ID 59600471600
Documents 17
Citations 25
h-index 3
Subject Area Pharmaceutical
Event International Top Pharmaceutical Awards
ORCID 0000-0002-8893-3248

Shweta Patel is a researcher associated with Gokul Global University, India, whose documented scholarly record includes pharmaceutical and medicinal chemistry research. Her recent work includes heterocyclic compound synthesis, antimicrobial evaluation, antioxidant studies, and ADME-oriented investigations. The available research record also identifies contributions involving green synthesis and computational assessment of chemical compounds.[1] :contentReference[oaicite:0]{index=0}

Abstract

The research profile of Shweta Patel reflects activity across pharmaceutical chemistry, medicinal chemistry, chemical synthesis, antimicrobial research, and computational drug-development approaches. Available records document studies involving pyran, oxadiazole, thiazolidinone, chromene, quinoline, and related heterocyclic frameworks. Several publications combine synthesis and characterization with biological or ADME-oriented evaluation, providing a multidisciplinary basis for pharmaceutical research.[2]

Keywords

Pharmaceutical Chemistry; Medicinal Chemistry; Drug Discovery; Heterocyclic Chemistry; Antimicrobial Research; Antioxidant Activity; ADME Prediction; Green Synthesis; Chemical Synthesis; Pharmaceutical Innovation.

Introduction

Pharmaceutical research increasingly integrates synthetic chemistry with biological screening and computational approaches to identify compounds with potentially useful pharmacological characteristics. Patel’s documented publications reflect this interdisciplinary pattern, particularly through investigations of heterocyclic derivatives and their antimicrobial or antioxidant properties. The research record also includes studies applying ADME prediction and green synthetic methodologies to pharmaceutical chemistry problems.[3]

Research Profile

The available Scopus-linked record identifies Shweta Patel with Scopus Author ID 59600471600, while the supplied ORCID record identifies 33 works across articles, book chapters, and other research outputs. The documented publication history spans at least 2023–2026 and includes journals such as the Journal of Pharmaceutical Innovation, Russian Journal of General Chemistry, Russian Journal of Organic Chemistry, and related scientific publications.[4]

Research Contributions

A recurring research theme is the design and synthesis of heterocyclic compounds followed by structural characterization and biological evaluation. Recent records include pyrazole–oxadiazole–thioacetamide hybrids, 1,8-naphthyridine–thiazolidinone derivatives, chromene–thiazolidinedione hybrids, and oxadiazole thioacetamide derivatives. These studies demonstrate an emphasis on connecting molecular design with antimicrobial activity and ADME-related assessment.[5]

Publications

The publication portfolio includes recent journal articles and earlier studies in synthetic and pharmaceutical chemistry. Documented examples include work on 2H-pyran derivatives, 1,3,4-oxadiazole derivatives, modified 2-oxochromane compounds, 1,4-dihydropyrano[2,3-c]pyrazoles, and 2-amino-4H-pyrans. The record also contains research on environmental applications of functionalized nanoparticles and pharmaceutical sedation comparisons.[4]

Research Impact

The supplied profile records 17 documents, 25 citations, and an h-index of 3 for the award profile. These metrics provide quantitative indicators of scholarly output and citation activity, although bibliometric values can change as databases are updated. The broader ORCID-linked record indicates additional works and research outputs beyond the selected metrics supplied for this recognition page.[4]

Award Suitability

The documented combination of pharmaceutical chemistry publications, heterocyclic synthesis, antimicrobial evaluation, antioxidant investigations, and ADME-focused research provides a clear scholarly basis for consideration within a pharmaceutical research recognition context. The record contains multiple peer-reviewed journal articles with DOI identifiers, allowing individual publications to be independently located and evaluated. Award consideration should be based on the applicable criteria and verified supporting documentation. [4]

Conclusion

Shweta Patel’s documented research activity encompasses several interconnected areas of pharmaceutical and medicinal chemistry, with particular emphasis on synthetic heterocyclic chemistry and biological evaluation. Her publication record includes recent DOI-indexed studies as well as earlier research on green synthesis and antimicrobial compounds. The available identifiers and publication records provide a basis for further scholarly verification and recognition assessment.

References

 

  1. Elsevier. (n.d.). Scopus author details: Shweta Patel, Author ID 59600471600. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=59600471600
  2. Patel, S. A. (2026). Development of a Novel 1,8-Naphthyridine–Thiazolidinone Derivative: Synthesis, Spectral Characterization, Antimicrobial Profiling, and ADME Prediction. Journal of Pharmaceutical Innovation. https://doi.org/10.1007/s12247-026-10426-z
  3. Patel, S. (2026). Structure–Activity Relationship and ADME-Guided Optimization of 4H-Chromene-3-Carbonitrile Derivatives as Promising Antimicrobial Agents. Research Square. https://doi.org/10.21203/rs.3.rs-8718836/v1
  4. Patel, S. (2026). Design and Synthesis of Pyrazole–Oxadiazole–Thioacetamide Hybrids with Antimicrobial and Antioxidant Properties. Journal of Pharmaceutical Innovation. https://doi.org/10.1007/s12247-026-10720-w
  5. Patel, S. (2026). Molecular hybridization approach toward quinoline–thiazolidinedione derivatives: synthesis, DPPH radical scavenging activity, and ADME prediction. Journal of the Iranian Chemical Society. https://doi.org/10.1007/s13738-026-03636-2

Cesar Poli | Biopharmaceutics | Innovative Research Award

Published on by Top Pharmaceutical

Innovative Research Award

Cesar Poli – Federal University of Rio Grande do Sul, Brazil

Cesar Poli
Affiliation Federal University of Rio Grande do Sul
Country Brazil
Scopus ID 13408393000
Documents 56
Citations 719
h-index 16
Subject Area Biopharmaceutics
Event International Top Pharmaceutical Awards
ORCID 0000-0002-8469-0779

Cesar Poli is a researcher and Associate Professor at the Federal University of Rio Grande do Sul (UFRGS), Brazil. His documented academic profile includes training in Agronomy, Animal Science and Pastoral Science, together with research activity involving sheep production, pasture management, production systems and ruminant nutrition. His ORCID record also identifies continuing academic employment at UFRGS and international research collaborations. [1]

Abstract

The Innovative Research Award profile recognizes the documented scholarly activities of Cesar Poli and presents his research record in an academic context. Available profile information records his association with UFRGS, postgraduate education, international collaborations, publication activity and peer-review participation. His research portfolio includes pasture-based production, sheep management, ruminant nutrition, animal behaviour and plant bioactive compounds. [1]

Keywords

Keywords: Cesar Poli, Innovative Research Award, Biopharmaceutics, Animal Science, Ruminant Nutrition, Pasture Management, Sheep Production, Grazing Systems, Plant Bioactive Compounds, Animal Behaviour, Livestock Research, Pharmaceutical Research.

Introduction

Cesar Poli’s academic career is associated with the Federal University of Rio Grande do Sul, where the ORCID record identifies him as an Associate Professor in Animal Science. His educational history includes an Agronomy degree from UFRGS, postgraduate study in Animal Science/Pastoral Science, and a Ph.D. from Massey University. These qualifications provide the documented foundation for his subsequent research and teaching activities. [1]

Research Profile

The available record describes research centered on the animal-plant interface, sheep production and management, production systems, pasture management, and integrated production and nutrition systems for ruminants. Recent publications address grazing intensity, tropical grass and legume pastures, tannins, lamb performance, animal behaviour and pasture characteristics. [2] [3]

Research Contributions

Poli’s publication record demonstrates sustained investigation of pasture-based livestock systems and nutritional factors affecting ruminant production. His documented studies include work on plant tannins, lamb growth, pasture structure, dietary preference and meat quality. A 2025 publication specifically examined plant tannin for grazing ruminant growth, while another investigated tropical grass and legume pastures grazed by lambs. [3] [4]

Publications

Cesar Poli has published research on pasture management, sheep production, ruminant nutrition, grazing behaviour, and plant bioactive compounds. His documented publications span recent studies and long-term research contributions in animal and pasture science. The research also covers lamb performance, pasture characteristics, dietary preference, and meat quality. His publication record demonstrates sustained scholarly engagement across animal science and related agricultural research areas. [1]

Research Impact

The supplied profile reports 56 documents, 719 citations and an h-index of 16 for the researcher. These bibliometric indicators provide quantitative measures of publication and citation activity, although they should be interpreted alongside disciplinary context, publication type and research collaboration. The ORCID record also documents international projects involving researchers and institutions across several countries. [1]

Award Suitability

For the International Top Pharmaceutical Awards, the Innovative Research Award profile can be considered in relation to the supplied subject classification of Biopharmaceutics and the researcher’s documented scientific record. His publications provide evidence of sustained research activity in biological production systems, nutrition, plant-derived compounds and animal science. Final award assessment should remain subject to the event’s formal evaluation criteria and independent review. [1]

Conclusion

Cesar Poli has a documented academic career at the Federal University of Rio Grande do Sul and a substantial publication record covering pasture management, sheep production, ruminant nutrition, animal behaviour and plant bioactive compounds. His ORCID record supports the chronology of his education, employment, research outputs and peer-review activity. These documented elements provide an academic basis for consideration within an innovation-focused recognition framework. [1]

References

  1. ORCID. (2026). Cesar Poli (0000-0002-8469-0779) – ORCID record. https://orcid.org/0000-0002-8469-0779
  2. Motta, J. H., Poli, C. H. E. C., Irigoyen, L. R., et al. (2026). Patterns of Plant Species Composition Under Different Grazing Intensity in Native Grasslands of Southern Brazil. Rangeland Ecology and Management. https://doi.org/10.1016/j.rama.2025.12.008
  3. Hampel, V. D. S., Poli, C. H. E. C., Tontini, J. F., et al. (2025). Physical and biochemical characteristics of tropical grass and legume pastures grazed by lambs. Grassland Science. https://doi.org/10.1111/grs.12433
  4. Poli, C. H. E. C., Tontini, J. F., Jacondino, L. R., et al. (2025). Plant tannin for grazing ruminant growth. Animal Frontiers. https://doi.org/10.1093/af/vfaf026
  5. Jacondino, L. R., Poli, C. H. E. C., Tontini, J. F., Correa, G., da Silva, I., Nigeliskii, A., Mello, R., Pereira, A., Magalhães, D., & Trindade, M., et al. (2024). Plant Bioactive Compounds of Brazilian Pampa Biome Natural Grasslands Affecting Lamb Meat Quality. Foods, 13(18), 2931. https://doi.org/10.3390/foods13182931

Bamidele Iwalokun | Immunoinformatics | Innovative Research Award

Published on by Top Pharmaceutical

Innovative Research Award

Bamidele Iwalokun — Nigerian Institute of Medical Research, Nigeria

Bamidele Iwalokun
Affiliation Nigerian Institute of Medical Research
Country Nigeria
Scopus ID 57217109793
Documents 92
Citations 1,482
h-index 23
Subject Area Immunoinformatics
Event International Top Pharmaceutical Awards
ORCID 0000-0003-4247-2797

Bamidele Iwalokun is a Nigerian biomedical researcher affiliated with the Nigerian Institute of Medical Research, where the supplied ORCID record identifies his employment as Head of Molecular Biology & Biotechnology. The same record identifies doctoral training in Biochemistry and documents a substantial body of scholarly works spanning molecular biology, infectious diseases, antimicrobial resistance, genomics and computational vaccine research. [1]

Abstract

Bamidele Iwalokun’s documented research profile encompasses molecular biology, biotechnology, infectious disease research, antimicrobial resistance, genomics and immunoinformatics. His publication record includes computational investigations of vaccine candidates and mRNA vaccine design, alongside laboratory and epidemiological studies of infectious diseases. The ORCID record supplied for this article documents multiple recent publications with established journal and DOI information. [2] [3]

Keywords

Immunoinformatics; vaccine design; mRNA vaccines; epitope-based vaccines; molecular biology; biotechnology; infectious diseases; antimicrobial resistance; genomics; computational biology; pharmaceutical research; vaccine development; biomedical innovation.

Introduction

Immunoinformatics applies computational methods to immunological data and is increasingly used to support the identification and evaluation of vaccine targets, epitopes and antigenic features. Such approaches can help organize complex biological information before experimental validation and may contribute to more systematic vaccine-development workflows. Iwalokun’s documented publications include several studies explicitly describing immunoinformatics-based approaches to vaccine design. [2]

Research Profile

His documented research profile intersects molecular biology, biotechnology, infectious disease microbiology and computational approaches to vaccine development. In particular, publications from 2024 describe immunoinformatics applications to Mokola virus, vaccinia and Mpox viruses, Epstein–Barr virus and hepatitis E virus. These works provide direct evidence for the relevance of immunoinformatics within his broader research portfolio. [2]

Research Contributions

The wider publication record includes research on multidrug-resistant organisms, resistance-associated genes, whole-genome sequencing and pathogen characterization. Examples include studies of methicillin-resistant Staphylococcus aureus, carbapenemase-producing Pseudomonas aeruginosa, multidrug-resistant Escherichia coli and molecular characteristics of other clinically important organisms. These investigations complement the computational research by addressing biological and microbiological questions relevant to infectious disease control. [5] [6]

Publications

The supplied ORCID record lists numerous scholarly works associated with Bamidele Iwalokun. Recent publications include research on infection prevention and control among healthcare workers in Nigerian COVID-19 treatment centres, the molecular landscape of methicillin-resistant Staphylococcus aureus, and computational vaccine-related studies. The record also identifies DOI information for these publications, providing persistent identifiers for scholarly verification.[4]

Research Impact

Beyond bibliometric indicators, the research record demonstrates activity across several interconnected biomedical themes. The combination of computational vaccine design, molecular characterization, antimicrobial resistance research and infectious disease studies provides a multidisciplinary foundation. This breadth may be particularly relevant to research recognition programs that consider methodological innovation and contribution to pharmaceutical or biomedical science. [1] [2]

Award Suitability

The documented research profile is substantively aligned with an Innovative Research Award because it contains peer-reviewed work applying computational and molecular approaches to contemporary vaccine-development questions. The immunoinformatics publications provide direct evidence of innovation-oriented research activity, particularly through computational vaccine design and epitope-based strategies. [4]

Conclusion

Bamidele Iwalokun’s documented scholarly profile represents a multidisciplinary research portfolio spanning molecular biology, biotechnology, infectious diseases, antimicrobial resistance and immunoinformatics. The combination of computational vaccine research and molecular infectious disease research provides a strong scholarly basis for considering the profile in the context of innovative pharmaceutical and biomedical research. The available publication evidence supports a neutral assessment of substantial research activity in areas that intersect immunoinformatics, vaccine development and translational biomedical science.[4]

References

  1. ORCID. (2026). Bamidele Iwalokun — ORCID record. ORCID.
    https://orcid.org/0000-0003-4247-2797
  2. Oladipo, E. K., Ogunniran, J. A., Akinpelu, O. S., Omole, T. O., Adeyemo, S. F., Irewolede, B. A., Iwalokun, B. A., Ajani, O. F., & Onyeaka, H. (2024). Bioinformatics designing of an mRNA vaccine for Mokola virus (MOKV) using immunoinformatics as a secure strategy for successful vaccine development. BMC Immunology.
    https://doi.org/10.1186/s12865-024-00668-2
  3. Oladipo, E. K., Oyelakin, O. D., Aiyelabegan, A. O., Olajide, E. O., Olatayo, V. O., Owolabi, K. P., Shittu, Y. B., Olugbodi, R. O., Ajala, H. A., et al. (2024). Exploring computational approaches to design mRNA vaccine against vaccinia and Mpox viruses. Immunity, Inflammation and Disease.
    https://doi.org/10.1002/iid3.1360
  4. Oladipo, E. K., Dairo, E. O., Bamigboye, C. O., Ajayi, A. F., Onile, O. S., Ariyo, O. E., Jimah, E. M., Oyawoye, O. M., Oloke, J. K., Iwalokun, B. A., et al. (2024). Harnessing immunoinformatics for precision vaccines: Designing epitope-based subunit vaccines against hepatitis E virus. BioMedInformatics, 4(3), 88.
    https://doi.org/10.3390/biomedinformatics4030088
  5. Olalekan, A., Bader, B. K., Iwalokun, B., Wolf, S., Lalremruata, A., Dike, A., Mannie-Udoh, M., Lo Presti, L., Liese, J., Guther, J., et al. (2023). High incidence of carbapenemase-producing Pseudomonas aeruginosa clinical isolates from Lagos, Nigeria. JAC-Antimicrobial Resistance.
    https://doi.org/10.1093/jacamr/dlad038

Onwu Daniel Ocha | Drug Discovery | Best Researcher Award

Published on by Top Pharmaceutical

Best Researcher Award

Onwu, Daniel Ocha
Affiliation University of Cross River State
Country Nigeria
Google Scholar ID n6jcvPsAAAAJ
Documents 9
Citations 2
h-index 1
Subject Area Drug Discovery
Event International Top Pharmaceutical Awards

Onwu Daniel Ocha – University of Cross River State

Onwu Daniel Ocha is a researcher affiliated with the University of Cross River State (UNICROSS), Calabar, Nigeria. His reported scholarly work is associated with computational biology, bioinformatics, drug discovery, network pharmacology, phytochemical investigation, and computational modelling. The supplied Google Scholar record reports nine documents, two citations, and an h-index of one. The profile also identifies computational biology and bioinformatics among the research areas associated with his scholarly activity.

Abstract

Onwu Daniel Ocha’s research profile reflects interdisciplinary activity connecting computational biology and bioinformatics with pharmaceutical and biomedical investigation. His available publication record includes research on phytochemicals, network pharmacology, computational modelling, biological targets, infectious diseases, and therapeutic investigation. These subjects are relevant to modern drug discovery because computational approaches can support the identification of candidate compounds, molecular targets, pathways, and potential mechanisms of action. His research record therefore demonstrates an emerging connection between computational science and pharmaceutical research. [1]

Keywords

Drug Discovery; Computational Biology; Bioinformatics; Network Pharmacology; Computational Modelling; Molecular Docking; Phytochemicals; Drug Target Identification; Systems Biology; Therapeutic Targeting; Pharmaceutical Research; In-silico Research; Biomedical Informatics.

Introduction

Computational biology and bioinformatics have become important components of modern pharmaceutical research. Computational approaches can be used to examine molecular interactions, biological pathways, disease-associated targets, and candidate therapeutic compounds before or alongside laboratory validation. Network pharmacology is particularly useful for studying complex relationships between compounds, proteins, pathways, and disease mechanisms. These approaches can contribute to the prioritization of potential therapeutic candidates and provide hypotheses for subsequent experimental research [1].

Research Profile

The supplied academic profile identifies Onwu Daniel Ocha with the University of Cross River State (UNICROSS), Calabar, Nigeria. His Google Scholar record reports nine documents, two citations, and an h-index of one. The research areas represented in the supplied profile include computational biology and bioinformatics, while the award profile specifically identifies Drug Discovery as the subject area. This combination places his research at the intersection of computational science and pharmaceutical investigation.[3]

Research Contributions

A notable contribution in the supplied publication record is the study titled In-Silico and Network Pharmacology Analysis of Mimosa invisa Phytochemicals against Testicular Inflammation. The work examines phytochemical compounds using computational approaches to investigate their potential relationships with inflammation-associated biological targets. This research direction is relevant to drug discovery because phytochemicals may provide candidate structures for further pharmacological investigation [3].

Publications

The available publication record demonstrates continuing scholarly activity in computational and biomedical research. Listed publications include studies on Mimosa invisa phytochemicals, biosynthesized silver nanoparticles, Terminalia catappa extracts, Allium cepa bioactive compounds, drug-resistant tuberculosis, Tefairia occidentalis phytocompounds, and computational analysis of antiviral targets. The diversity of these topics indicates an interdisciplinary research approach involving computational methods and biological investigation.[3].

Research Impact

The supplied Google Scholar profile reports two citations and an h-index of one. These bibliometric indicators represent the citation activity recorded by the profile at the time of the supplied document and may change as additional publications are indexed and cited. Therefore, citation indicators should be considered together with publication quality, research relevance, collaboration, and scientific contribution when assessing an emerging researcher.[4].

Award Suitability

The award assessment should nevertheless remain evidence-based and should consider the complete research portfolio, verified publication records, originality, methodological quality, scholarly contribution, collaboration, and the official eligibility criteria established by the award organizers. The available profile demonstrates an emerging publication record rather than providing sufficient evidence for unsupported claims of exceptional impact. This distinction maintains a neutral academic approach to recognition[4].

Conclusion

Onwu Daniel Ocha’s documented research profile demonstrates interdisciplinary activity involving computational biology, bioinformatics, drug discovery, network pharmacology, phytochemicals, and systems biology. The supplied record identifies nine documents, two citations, and an h-index of one, while the listed publications demonstrate research activity across several biomedical and pharmaceutical themes. [1].

References

  1. Onwu, D. O., Uraku, O. H., Agbi, M. T., & Uraku, A. J. (2026). In-silico and network pharmacology analysis of Mimosa invisa phytochemicals against testicular inflammation. In Silico Research in Biomedicine, 2, 100274.
    https://doi.org/10.1016/j.insi.2026.100274
  2. Onwu, D., Edun, S., Asuquo, U., & Bajepade, T. I. (2025). Antidiabetic potential of biosynthesized silver nanoparticles with fresh guava leaf. Covenant Journal of Physical and Life Sciences, 13(2), 1–6.
    https://journals.covenantuniversity.edu.ng/index.php/cjpls/article/view/4978
  3. Onwu, D. O., Kayode, D., Oluwatosin, C. E., Chimaobi, N. G., Johnson, O., et al. (2026). Assessing the effects of aqueous extract of Terminalia catappa on immunoglobulins levels in cyclophosphamide induced immunosuppressant Wistar rats. Next Research, 101441.
    https://doi.org/10.1016/j.nexres.2026.101441
  4. Onwu, D. O., Singh, A., Bajpai, Y., Akinlamilo, A. S., Habiganuchi, A., & Ibikunle, F. O. (2025). Host–pathogen interaction mapping in drug-resistant tuberculosis: A systems biology framework for dual therapeutic targeting. Research Square.
    https://doi.org/10.21203/rs.3.rs-7855974/v1
  5. Ahmad, A., Nnenna, A. O., Mamman, S., Nwokoro, C., Bello, A. M., Nseabasi, M. A., Abdulwakiil, M., Okpe, J., Onwu, D. O., Agbi, M., & Idoko, A. (2025). In-silico network pharmacology and computational modelling of bioactive compounds from Allium cepa targeting downstream protein effectors in diabetes. Research Square.
    https://doi.org/10.21203/rs.3.rs-8181479/v1

Naglaa Shehab | Drug Discovery and Development | Editorial Board Member

Published on by Top Pharmaceutical

Editorial Board Member

Naglaa Shehab — Dubai Medical University
Naglaa Shehab
Affiliation Dubai Medical University
Country United Arab Emirates
Scopus ID 26424069600
Documents 446
Citations 494
h-index 13
Subject Area Drug Discovery and Development
Event International Top Pharmaceutical Awards
ORCID 0000-0002-7514-4055

Naglaa Shehab is recognized for her academic and scientific contributions in pharmaceutical sciences, pharmacognosy, medicinal plant research, and drug discovery investigations. Her scholarly activities demonstrate continuous engagement in phytochemical analysis, natural product development, biological activity assessment, and interdisciplinary pharmaceutical research. Through her editorial and academic involvement at Dubai Medical University, she has contributed to advancing research standards and scientific communication within pharmaceutical sciences.[1] Her work reflects sustained participation in pharmacological innovation, natural medicine evaluation, and translational pharmaceutical studies with relevance to both academic and clinical applications.[2]

Abstract

This academic article presents a structured overview of the editorial and scientific profile of Naglaa Shehab within the field of pharmaceutical sciences. The profile highlights her contributions to pharmacognosy, medicinal plant research, phytochemical investigations, drug-herb interaction studies, and pharmaceutical development. Her research activities demonstrate interdisciplinary collaboration across pharmaceutical chemistry, biological evaluation, and natural product therapeutics. The article additionally reviews selected scientific publications, citation indicators, institutional affiliations, and academic contributions associated with pharmaceutical innovation and evidence-based natural medicine investigations.[1]

Keywords

Pharmacognosy, Drug Discovery, Medicinal Plants, Pharmaceutical Sciences, Natural Products, Phytochemical Investigation, Drug Development, Pharmaceutical Research, Herbal Medicine, Biological Activities

Introduction

Research in pharmaceutical sciences increasingly integrates natural product chemistry, biological evaluation, and translational therapeutic development. Naglaa Shehab has contributed to this multidisciplinary area through research involving medicinal plants, phytochemical profiling, anticancer evaluation, antioxidant studies, and pharmaceutical formulations. Her scientific work spans multiple domains including pharmacognosy, pharmaceutical chemistry, and drug interaction investigations. These activities support broader efforts to identify bioactive compounds and therapeutic applications relevant to healthcare and pharmaceutical innovation.[3]

Research Profile

Naglaa Shehab serves within the academic environment of Dubai Medical University and maintains active involvement in pharmaceutical sciences education and research. Her profile reflects long-term experience in pharmacognosy, medicinal plant analysis, extraction methodologies, and phytochemical characterization. Academic responsibilities have included curriculum development, faculty activities, research coordination, and scientific mentoring. Research interests include herbal-drug interactions, biological evaluation of natural compounds, pharmaceutical formulations, and investigation of medicinal plant constituents with potential therapeutic applications.[1]

  • Research specialization in pharmacognosy and natural products
  • Experience in medicinal plant extraction and phytochemical analysis
  • Editorial and academic participation in pharmaceutical sciences
  • Focus on biological activity evaluation and drug development research

Research Contributions

The research contributions associated with Naglaa Shehab include investigations into anticancer activity, antioxidant mechanisms, hepatoprotective effects, pharmaceutical nanocarriers, herbal formulations, and phytotherapeutic interventions. Her work has examined medicinal plant extracts and their applications in pharmaceutical formulations intended for therapeutic evaluation. Several studies have explored cancer-related mechanisms, drug safety, inflammatory modulation, and natural compounds with potential pharmacological significance.[2][4]

  • Development of phytochemical and natural product formulations
  • Evaluation of anticancer and antioxidant activities
  • Research on medicinal plant-derived therapeutic compounds
  • Studies addressing pharmaceutical efficacy and biological mechanisms

Publications

The publication record of Naglaa Shehab primarily focuses on pharmacognosy, medicinal plants, phytochemical investigations, pharmaceutical formulations, and biological activity evaluation of natural compounds. Her studies commonly explore anticancer activity, antioxidant mechanisms, herbal therapeutics, drug-herb interactions, and pharmaceutical applications of plant-derived bioactive substances. Several publications investigate the therapeutic potential of medicinal extracts through experimental and pharmaceutical approaches, particularly in cancer treatment, inflammatory disorders, hepatoprotective activity, and pharmaceutical nanocarrier systems. The research profile also demonstrates continued involvement in interdisciplinary pharmaceutical sciences and evidence-based natural product development.[3][4]

Research Impact

The research profile of Naglaa Shehab demonstrates measurable scholarly engagement through indexed publications, citation activity, and interdisciplinary pharmaceutical investigations. Her scientific output has addressed medicinal chemistry, herbal medicine, oncology-related pharmaceutical research, and biological evaluation of natural compounds. The documented h-index and citation metrics indicate ongoing academic visibility within pharmaceutical and pharmacognosy-related research communities.[1][5]

Award Suitability

Naglaa Shehab demonstrates suitability for recognition within pharmaceutical and biomedical academic platforms due to her contributions to drug discovery, pharmacognosy, medicinal plant investigations, and pharmaceutical sciences education. Her participation in scientific publishing, interdisciplinary collaborations, and research development aligns with the objectives of international pharmaceutical recognition initiatives. The combination of research productivity, editorial engagement, and pharmaceutical innovation supports her relevance to academic award and editorial board recognition programs.[5]

Conclusion

The academic profile of Naglaa Shehab reflects continued engagement in pharmaceutical sciences, medicinal plant investigations, and natural product research. Her scholarly contributions encompass pharmaceutical formulations, phytochemical analysis, biological evaluation, and interdisciplinary healthcare applications. Through editorial participation, scientific publications, and pharmaceutical research activities, she contributes to ongoing developments within drug discovery and pharmaceutical innovation.[1][2]

References

  1. ORCID. (2026). Naglaa Shehab ORCID profile and academic activities. ORCID Registry.https://orcid.org/0000-0002-7514-4055
  2. Elsevier. (n.d.). Scopus author details: Naglaa Shehab, Author ID 26424069600. Scopus.https://www.scopus.com/authid/detail.uri?authorId=26424069600
  3. Khalifa, A., Shehab, N.G., et al. (2026). Development of Phyllanthus emblica Extract-Loaded Niosomes for Cancer Treatment: Formulation and In Vitro Evaluation. Pharmaceuticals.DOI:https://doi.org/10.3390/ph19040582
  4. Bou Malhab, L.J., Shehab, N.G., et al. (2023). Potential Anticancer Properties of Calotropis procera: An Investigation on Breast and Colon Cancer Cells. Heliyon.DOI:https://doi.org/10.1016/j.heliyon.2023.e16706
  5. Anbar, H.S., El Wakil, A., Shehab, N.G., et al. (2024). The wound healing and hypoglycemic activates of date palm (Phoenix dactylifera) leaf extract and saponins in diabetic and normal rats. PLOS ONE.
    DOI: https://doi.org/10.1371/journal.pone.0308879

Aniela Montserrat Silva Nolasco | Pharmaceutical Chemistry | Excellence in Research Award

Published on by Top Pharmaceutical

Excellence in Research Award


Aniela Montserrat Silva Nolasco

Universidad de Castilla-La Mancha, Spain


Aniela Montserrat Silva Nolasco
Affiliation Universidad de Castilla-La Mancha
Country Spain
Scopus ID
57221107566
Documents 21
Citations 23
h-index 2
Subject Area Pharmaceutical Chemistry
Event International Top Pharmaceutical Awards

Aniela Montserrat Silva Nolasco is a pharmaceutical science researcher associated with Universidad de Castilla-La Mancha, Spain. Her academic profile demonstrates research engagement in molecular pharmacology, pharmaceutical chemistry, cancer biology, and bioactive therapeutic compounds. Published studies associated with her scholarly work examine anticancer properties of argentatins, immunomodulatory activity, and translational therapeutic applications in oncology-related biomedical sciences.[1] Her research contributions are indexed through recognized academic databases including Scopus and ORCID, supporting international visibility and scientific dissemination within pharmaceutical and biomedical research communities.[2]

Abstract

This article summarizes the academic contributions and pharmaceutical research activities of Aniela Montserrat Silva Nolasco. The profile reflects scholarly involvement in cancer biology, molecular pharmacology, pharmaceutical chemistry, and translational therapeutic research involving argentatin compounds and related bioactive agents.[3] Indexed publications, DOI-linked research outputs, and collaborative scientific studies contribute to the researcher’s academic visibility within pharmaceutical and biomedical sciences.[4]

Keywords

Pharmaceutical Chemistry, Molecular Pharmacology, Anticancer Research, Argentatins, Cancer Biology, Translational Medicine, Immunomodulation, Biomedical Sciences, Oncology Research, Therapeutic Compounds.

Introduction

Pharmaceutical research associated with molecular therapeutics and cancer-related biomedical investigations continues to contribute substantially to contemporary translational medicine. Current scientific developments increasingly emphasize naturally derived compounds with potential therapeutic applications against tumor progression and immune dysregulation.[5] Research contributions associated with Aniela Montserrat Silva Nolasco demonstrate participation in this evolving pharmaceutical research landscape through investigations involving argentatins and cellular pharmacological mechanisms.[6]

Research Profile

The academic profile of Aniela Montserrat Silva Nolasco includes affiliations with Universidad de Castilla-La Mancha and previous research and educational activities associated with pharmaceutical and molecular sciences. Her scholarly background includes pharmaceutical biology, cellular pharmacology, and laboratory-based biomedical investigations relevant to therapeutic development and oncology-focused pharmaceutical sciences.[2]

The Scopus profile linked to the researcher identifies indexed publication activity, citation tracking, and collaborative research participation within pharmaceutical and biomedical disciplines. These indicators support measurable academic visibility and ongoing scholarly communication across internationally indexed scientific platforms.[1]

Research Contributions

Research contributions associated with Aniela Montserrat Silva Nolasco include investigations on argentatin compounds and their biological activity in cancer-related cellular environments. Published studies report antimigratory and antiangiogenic effects alongside analyses of long-term resistance induction associated with argentatin A and argentatin B.[3]

Additional scientific contributions address immunomodulatory activity isolated from guayule-derived compounds and synergistic therapeutic interactions involving 5-fluorouracil in colorectal cancer cell models. These studies contribute to broader translational pharmaceutical research exploring molecular therapeutic strategies in oncology-related biomedical sciences.[4]

Publications

The publication profile associated with Aniela Montserrat Silva Nolasco includes peer-reviewed research outputs indexed through recognized scientific databases. DOI-linked publications contribute to scholarly accessibility, research transparency, and international academic dissemination within pharmaceutical chemistry and molecular biomedical sciences.[3][4]

DOI-linked publications facilitate long-term accessibility and citation reliability within digital academic infrastructures. The use of persistent identifiers further supports research transparency, discoverability, and scholarly preservation across multidisciplinary scientific environments.[3]

Research Impact

Research impact is commonly evaluated using publication visibility, citation performance, indexed dissemination, and scholarly engagement across scientific communities. The researcher’s profile demonstrates documented participation in peer-reviewed pharmaceutical and biomedical research activities through Scopus-indexed publications and DOI-associated scholarly outputs.[1]

The available citation indicators and publication metrics support measurable academic relevance within specialized pharmaceutical chemistry and translational biomedical research domains. Continued scientific dissemination and collaborative publication activity may further strengthen long-term academic visibility and research influence.[2]

Award Suitability

The research activities and scholarly outputs associated with Aniela Montserrat Silva Nolasco align with the objectives of the International Top Pharmaceutical Awards through contributions to pharmaceutical chemistry, cancer-related therapeutic investigations, and molecular biomedical sciences.[6] The profile reflects participation in interdisciplinary scientific studies relevant to pharmaceutical innovation and translational therapeutic development.[3]

Conclusion

Aniela Montserrat Silva Nolasco has contributed to pharmaceutical and biomedical research through studies involving anticancer compounds, immunomodulatory activity, and molecular therapeutic investigations. Her academic profile demonstrates scholarly engagement within pharmaceutical chemistry and translational medicine, supported by indexed publications, collaborative research contributions, and DOI-linked scientific dissemination.[5]

References

  1. Elsevier. (n.d.). Scopus author details: Aniela Montserrat Silva Nolasco, Author ID 57221107566. Scopus.https://www.scopus.com/authid/detail.uri?authorId=57221107566
  2. ORCID. (2026). Aniela M. Silva-Nolasco ORCID profile, affiliations, and academic activities.https://orcid.org/0000-0002-2134-7551
  3. Silva-Nolasco, A. M., Galvez, B. G., de la Cruz-Morcillo, M. A., & Carmona, M. (2026). Differential anti-cancer effects of argentatin A and B: antimigratory, antiangiogenic, and long-term resistance induction. Industrial Crops and Products.https://doi.org/10.1016/j.indcrop.2026.123255
  4. Silva-Nolasco, A. M., Singh, N., de la Cruz-Morcillo, M. A., García-Martínez, M. M., Zalacain, A., Gálvez, B. G., & Carmona, M. (2024). Immunomodulatory activity of argentatins A and B isolated from guayule. PLOS ONE.https://doi.org/10.1371/journal.pone.0304713
  5. Sánchez‐Olivares, P., Silva‐Nolasco, A. M., de la Cruz‐Morcillo, M. A., García‐Martínez, M. M., Pinedo‐Serrano, A., Carmona, M., & Galán‐Moya, E. M. (2024). Synergistic Potential of Argentatins A and B to Improve 5‐Fluorouracil Cytotoxicity in Colorectal Cancer Cell Models. Journal of Cellular and Molecular Medicine.https://doi.org/10.1111/jcmm.70294

Gul Wali Khan | Medicinal Chemistry | Research Excellence Award

Published on by Top Pharmaceutical

Mr. Gul Wali Khan | Medicinal Chemistry | Research Excellence Award

Research Assistant | Vorozhtsov Novosibirsk Institute of Organic Chemistry | Pakistan

Mr. Gul Wali Khan is a Research Assistant in organic chemistry at the Novosibirsk Institute of Organic Chemistry, specializing in organometallic synthesis and characterization. He holds advanced degrees in chemistry with a strong focus on organic and coordination chemistry, including research on ferrocene-based bimetallic complexes and ligand design. His professional experience includes extensive laboratory research involving experimental design, spectroscopic characterization, data analysis, and collaborative scientific reporting, alongside prior academic roles in teaching and mentoring chemistry students. His research focuses on the synthesis, structural analysis, and biological evaluation of metal-based complexes, contributing to the advancement of organometallic chemistry with applications in antimicrobial studies and material science. He has authored peer-reviewed publications in reputable journals and is actively engaged in ongoing research projects, demonstrating consistent scholarly output. His contributions reflect a commitment to high-quality research, interdisciplinary collaboration, and growing academic impact, positioning him as a promising candidate for recognition in research excellence.

Citation Metrics (Google Scholar)

11
8
5
2
0

1

1

1

Citations

Documents

h-index

 


Featured Publications

Naglaa Shehab| Drug Discovery and Development | Research Excellence Award

Published on by Top Pharmaceutical

Prof. Dr. Naglaa Shehab| Drug Discovery and Development | Research Excellence Award

Professor | Dubai Medical University | United Arab Emirates 

Prof. Naglaa Gamil Shehab is a Professor of Pharmaceutical Sciences at Dubai Medical University, specializing in pharmacognosy, phytochemistry, medicinal plants, and complementary medicine. She holds advanced degrees in pharmacognosy with a strong foundation in phytochemical research and natural product analysis. Her academic career spans progressive roles from teaching and research to senior professorship and academic leadership, including key responsibilities in curriculum development and coordination of multidisciplinary pharmaceutical courses. Her research focuses on the pharmacognostical and phytochemical investigation of medicinal plants, contributing to the validation of natural therapies and alternative medicine through scientific methodologies. With a notable citation record, consistent publication output, and measurable scholarly impact, she has established herself as a recognized contributor to pharmaceutical sciences. She is actively engaged in academic service through editorial contributions, professional memberships, and mentorship of emerging researchers, reflecting sustained commitment to advancing research quality and innovation in pharmacognosy and related disciplines.

Citation Metrics (Google Scholar)

779
600
400
200
0

779

18

14

Citations

i10-index

h-index


Top 5 Featured Publications